Myocardial energetics and efficiency in patients with idiopathic cardiomyopathy

Response to dobutamine and amrinone

Ponnambalam Sundram, Hanumanth K. Reddy, Patricia A. McElroy, Joseph S. Janicki, Karl Weber

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Nine consecutive patients having severer idiopathic dilated cardiomyopathy were studied for their response in ventricular function, coronary sinus blood flow and myocardial oxygen consumption, lactate extraction and efficiency following incremental doses of dobutamine, followed by the combination of dobutamine and the phosphodiesterase inhibitor amrinone. Results, presented as baseline and the response to the peak dose (15μg/kg/min) of dobutamine and to the combination of dobutamine and amrinone (each at 15 μg/kg/min) (differences compared with baseline) were: wedge pressure decreased from 28±7 to 26±8 mm Hg (p=NS) and to 20±6 mm Hg (p<0.01); cardiac index rose from 1.47±0.44 L/min/m2 to 2.80±1.1 L/min/m2 (p<0.01) and to 3.64±1.05 L/min/m2 (p<0.001); myocardial oxygen consumption minute work fror (18±8, 17±5, and 19±5 ml/min) despite progressive increments in (p<0.001); myocardial lactate extraction rose from 21±10% to 30±15% (p=NS) and to 35±10% with the addition of amrinone (p<0.01). No patient had net lactate efflux into the coronary sinus, and myocardial efficiency improved from 9.5±5% to 21.7±13.0% (p<0.01) and to 28.0±18.0% (p<0.01). Thus in idiopathic dilated cardiomyopathy, dobutamine and the combination of dobutamine and amrinone have additive beneficial effects on ventricular performance without an adverse elevation in myocardial oxygen consumption or lactate production, resulting in improved efficiency, suggesting the presence of significant metabolic reserve within the failing myocardium.

Original languageEnglish (US)
Pages (from-to)891-898
Number of pages8
JournalAmerican Heart Journal
Volume119
Issue number4
DOIs
StatePublished - Jan 1 1990
Externally publishedYes

Fingerprint

Amrinone
Dobutamine
Cardiomyopathies
Lactic Acid
Oxygen Consumption
Coronary Sinus
Dilated Cardiomyopathy
Pulmonary Wedge Pressure
Phosphodiesterase Inhibitors
Ventricular Function
Myocardium

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Myocardial energetics and efficiency in patients with idiopathic cardiomyopathy : Response to dobutamine and amrinone. / Sundram, Ponnambalam; Reddy, Hanumanth K.; McElroy, Patricia A.; Janicki, Joseph S.; Weber, Karl.

In: American Heart Journal, Vol. 119, No. 4, 01.01.1990, p. 891-898.

Research output: Contribution to journalArticle

Sundram, Ponnambalam ; Reddy, Hanumanth K. ; McElroy, Patricia A. ; Janicki, Joseph S. ; Weber, Karl. / Myocardial energetics and efficiency in patients with idiopathic cardiomyopathy : Response to dobutamine and amrinone. In: American Heart Journal. 1990 ; Vol. 119, No. 4. pp. 891-898.
@article{983a645793b548fabcf7466c1b8f998d,
title = "Myocardial energetics and efficiency in patients with idiopathic cardiomyopathy: Response to dobutamine and amrinone",
abstract = "Nine consecutive patients having severer idiopathic dilated cardiomyopathy were studied for their response in ventricular function, coronary sinus blood flow and myocardial oxygen consumption, lactate extraction and efficiency following incremental doses of dobutamine, followed by the combination of dobutamine and the phosphodiesterase inhibitor amrinone. Results, presented as baseline and the response to the peak dose (15μg/kg/min) of dobutamine and to the combination of dobutamine and amrinone (each at 15 μg/kg/min) (differences compared with baseline) were: wedge pressure decreased from 28±7 to 26±8 mm Hg (p=NS) and to 20±6 mm Hg (p<0.01); cardiac index rose from 1.47±0.44 L/min/m2 to 2.80±1.1 L/min/m2 (p<0.01) and to 3.64±1.05 L/min/m2 (p<0.001); myocardial oxygen consumption minute work fror (18±8, 17±5, and 19±5 ml/min) despite progressive increments in (p<0.001); myocardial lactate extraction rose from 21±10{\%} to 30±15{\%} (p=NS) and to 35±10{\%} with the addition of amrinone (p<0.01). No patient had net lactate efflux into the coronary sinus, and myocardial efficiency improved from 9.5±5{\%} to 21.7±13.0{\%} (p<0.01) and to 28.0±18.0{\%} (p<0.01). Thus in idiopathic dilated cardiomyopathy, dobutamine and the combination of dobutamine and amrinone have additive beneficial effects on ventricular performance without an adverse elevation in myocardial oxygen consumption or lactate production, resulting in improved efficiency, suggesting the presence of significant metabolic reserve within the failing myocardium.",
author = "Ponnambalam Sundram and Reddy, {Hanumanth K.} and McElroy, {Patricia A.} and Janicki, {Joseph S.} and Karl Weber",
year = "1990",
month = "1",
day = "1",
doi = "10.1016/S0002-8703(05)80328-X",
language = "English (US)",
volume = "119",
pages = "891--898",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Myocardial energetics and efficiency in patients with idiopathic cardiomyopathy

T2 - Response to dobutamine and amrinone

AU - Sundram, Ponnambalam

AU - Reddy, Hanumanth K.

AU - McElroy, Patricia A.

AU - Janicki, Joseph S.

AU - Weber, Karl

PY - 1990/1/1

Y1 - 1990/1/1

N2 - Nine consecutive patients having severer idiopathic dilated cardiomyopathy were studied for their response in ventricular function, coronary sinus blood flow and myocardial oxygen consumption, lactate extraction and efficiency following incremental doses of dobutamine, followed by the combination of dobutamine and the phosphodiesterase inhibitor amrinone. Results, presented as baseline and the response to the peak dose (15μg/kg/min) of dobutamine and to the combination of dobutamine and amrinone (each at 15 μg/kg/min) (differences compared with baseline) were: wedge pressure decreased from 28±7 to 26±8 mm Hg (p=NS) and to 20±6 mm Hg (p<0.01); cardiac index rose from 1.47±0.44 L/min/m2 to 2.80±1.1 L/min/m2 (p<0.01) and to 3.64±1.05 L/min/m2 (p<0.001); myocardial oxygen consumption minute work fror (18±8, 17±5, and 19±5 ml/min) despite progressive increments in (p<0.001); myocardial lactate extraction rose from 21±10% to 30±15% (p=NS) and to 35±10% with the addition of amrinone (p<0.01). No patient had net lactate efflux into the coronary sinus, and myocardial efficiency improved from 9.5±5% to 21.7±13.0% (p<0.01) and to 28.0±18.0% (p<0.01). Thus in idiopathic dilated cardiomyopathy, dobutamine and the combination of dobutamine and amrinone have additive beneficial effects on ventricular performance without an adverse elevation in myocardial oxygen consumption or lactate production, resulting in improved efficiency, suggesting the presence of significant metabolic reserve within the failing myocardium.

AB - Nine consecutive patients having severer idiopathic dilated cardiomyopathy were studied for their response in ventricular function, coronary sinus blood flow and myocardial oxygen consumption, lactate extraction and efficiency following incremental doses of dobutamine, followed by the combination of dobutamine and the phosphodiesterase inhibitor amrinone. Results, presented as baseline and the response to the peak dose (15μg/kg/min) of dobutamine and to the combination of dobutamine and amrinone (each at 15 μg/kg/min) (differences compared with baseline) were: wedge pressure decreased from 28±7 to 26±8 mm Hg (p=NS) and to 20±6 mm Hg (p<0.01); cardiac index rose from 1.47±0.44 L/min/m2 to 2.80±1.1 L/min/m2 (p<0.01) and to 3.64±1.05 L/min/m2 (p<0.001); myocardial oxygen consumption minute work fror (18±8, 17±5, and 19±5 ml/min) despite progressive increments in (p<0.001); myocardial lactate extraction rose from 21±10% to 30±15% (p=NS) and to 35±10% with the addition of amrinone (p<0.01). No patient had net lactate efflux into the coronary sinus, and myocardial efficiency improved from 9.5±5% to 21.7±13.0% (p<0.01) and to 28.0±18.0% (p<0.01). Thus in idiopathic dilated cardiomyopathy, dobutamine and the combination of dobutamine and amrinone have additive beneficial effects on ventricular performance without an adverse elevation in myocardial oxygen consumption or lactate production, resulting in improved efficiency, suggesting the presence of significant metabolic reserve within the failing myocardium.

UR - http://www.scopus.com/inward/record.url?scp=0025366629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025366629&partnerID=8YFLogxK

U2 - 10.1016/S0002-8703(05)80328-X

DO - 10.1016/S0002-8703(05)80328-X

M3 - Article

VL - 119

SP - 891

EP - 898

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 4

ER -